E-cigarettes may be more effective in helping pregnant smokers quit

May.17.2022
E-cigarettes may be more effective in helping pregnant smokers quit
Pregnant smokers using e-cigarettes are more likely to quit smoking compared to nicotine patch users, according to a study.

Research shows that pregnant smokers are more likely to quit smoking using electronic cigarettes after four weeks than nicotine patches.

 

Researchers have discovered that electronic cigarettes may be equally safe for pregnant women trying to quit smoking as nicotine patches, and may even be a more effective tool.

 

Smoking during pregnancy increases the risk of adverse outcomes such as preterm birth, miscarriage, and low birth weight. However, quitting this habit can be a challenging process.

 

Dr. Francesca Pesola from Queen Mary University of London, the author of this new study, stated that "many pregnant smokers find it difficult to quit smoking using current cessation aids (including nicotine patches) and continue smoking throughout their pregnancy.

 

Although it has been discovered that electronic cigarettes are more effective than nicotine patches in helping people quit smoking, Pesola points out that despite the increasing use of electronic cigarettes by pregnant women, research on their effectiveness or safety is scarce.

 

After attempting to quit smoking for four weeks, 15.4% of individuals who reported using e-cigarettes said that they no longer smoke, compared to only 8.6% of those using nicotine patches.

 

Smoking during pregnancy increases the risk of negative outcomes, including premature birth, miscarriage, and low birth weight for the infant. However, quitting this habit can be a challenging process.

 

Although electronic cigarettes have been shown to be more effective than nicotine patches in helping people quit smoking, Pesola points out that despite an increase in the use of e-cigarettes among pregnant women, there is little research on their effectiveness or safety.

 

Researchers led by Pesola reported in the journal Nature Medicine that they randomly assigned 569 pregnant smokers to use e-cigarettes and 571 pregnant women to use nicotine patches – a nicotine replacement therapy that can already be prescribed during pregnancy. The participants were an average of 15.7 weeks pregnant and smoked 10 cigarettes per day.

 

Only 40% of participants received an electronic cigarette and 23% received a patch, both of which were used for at least four weeks. However, during the study period, those who received electronic cigarettes had higher usage rates and longer usage times.

 

Excluding participants who self-reported not smoking but using nicotine products other than those assigned to them, such as those using nicotine patches along with e-cigarettes, the research team found that those who received e-cigarettes appeared to do better in terms of smoking cessation.

 

After attempting to quit smoking for four weeks, 15.4% of individuals self-reported that they had not smoked, compared to only 8.6% of those who were given patches. At the end of their pregnancies, 19.8% of the e-cigarette group self-reported that they had quit smoking, while only 9.7% of the patch group had done so.

 

Only a small number of participants provided saliva samples to confirm smoking cessation at the end of pregnancy, but once those who used unassigned products were excluded, the research group found that the quit rates among the electronic cigarette group were higher.

 

Additionally, the research team found that the incidence of adverse events was similar between individuals who were given cigarettes and those who were given patches. More importantly, although the average birth weight of infants was similar, low birth weight was more common in the patch group.

 

However, this study has limitations, including low compliance and the use of electronic cigarettes that differ from modern devices.

 

The author further stated that due to the potential risks of nicotine during pregnancy, it is best for pregnant women to quit smoking without using nicotine-containing products.

 

Pesola stated, "We only recommend nicotine use for smokers who wish to quit traditional cigarettes.

 

However, she added, "The risks posed to mothers or infants by using electronic cigarettes are no greater than those posed by nicotine patches. Both are better choices than continuing to smoke throughout the entire course of pregnancy.

 

Source: The Guardian

 

E-cigarettes are equally safe as nicotine patches for pregnant women who smoke and are attempting to quit, according to a report in The Guardian on May 16, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10